[(2S)-3-(1H-imidazol-1-ium-4-yl)-1-methoxy-1-oxopropan-2-yl]azanium;dichloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2S)-3-(1H-imidazol-1-ium-4-yl)-1-methoxy-1-oxopropan-2-yl]azanium;dichloride
• 化学式: C7H13Cl2N3O2
• mdl: MFCD00012701
• 分子量: 242.1
• InChiKey: DWAYENIPKPKKMV-ILKKLZGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.87
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  81
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [(2S)-3-(1H-imidazol-1-ium-4-yl)-1-methoxy-1-oxopropan-2-yl]azanium;dichloride 以100%的产率得到
  参考文献：
  名称：

  VOCITER, WOLFGANG

  摘要：

  DOI：
• 作为产物：
  描述：

  L-组氨酸 生成 [(2S)-3-(1H-imidazol-1-ium-4-yl)-1-methoxy-1-oxopropan-2-yl]azanium;dichloride
  参考文献：
  名称：

  RYONO, DENIS E.;WELLER, HAROLD N. (III)

  摘要：

  DOI：

文献信息

• Pyrazolopyrimidines as therapeutic agents
  申请人：Abbott Laboratories

  公开号：US20020156081A1

  公开（公告）日：2002-10-24

  The present invention provides compounds of Formula I, 1 including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R 2 , and R 3 are defined as described herein.

  本发明提供了公式I的化合物，包括其药学上可接受的盐和/或前药，其中G、R2和R3的定义如本文所述。
• Novel amino acid derivatives possessing renin-inhibitory activities
  申请人：Japan Tobacco Inc.

  公开号：EP0396065A1

  公开（公告）日：1990-11-07

  An amino acid derivative of the general formula: wherein R1 is wherein, R10 is a lower alkyl group and R" is (wherein R111 is a lower alkyl group and n is an integer of 1 to 5) or a lower alkyl group which may be substituted by hydroxy group or methoxyethoxymethoxy group, or R'° and R" are combinedly together with the adjacent nitrogen atom; R12 is a hydrogen atom, CnH2n+1-O-CO- (n is as defined above) or R'3 is a lower alkyl group which may be substituted by substituent(s) selected from HOOC-(H2C)n-O-, R12- NH- (n and R12 are as defined above) and pyridyl group; X is -CH2-, -O- or -NH- and Y is -O- or -NH-; wherein (wherein Z is -0-, -S-, -S(O)-. -S(O)2-, -CH2-, -CH(OH)-, or and a and b are independently an integer of 1 to 4 and the total of a and b is not more than 5) ; R2 is an aralkyl group which may be substituted by lower alkyl group(s); R3 is a hydrogen atom or a lower alkyl group; R4 is a lower alkyl group; and A is hydroxy group and B is a hydrogen atom, or A and B are carbonyl group combinedly together with the adjacent carbon atom, a pharmaceutically acceptable acid addition salt or an ester thereof is described. The compounds of the invention possess inhibitory activities against renin and are useful as an antihypertensive agent.

  通用公式的氨基酸衍生物： 其中R1为 其中，R10为较低的烷基基团，R"为 （其中R111为较低的烷基基团，n为1至5的整数）或者可以被羟基或甲氧乙氧甲氧基取代的较低烷基基团，或者R'°和R"与相邻的氮原子 结合在一起； R12为氢原子，CnH2n+1-O-CO-（n如上定义）或者 R'3为可以被HOOC-(H2C)n-O-、R12-NH-（n和R12如上定义）和吡啶基取代的较低烷基基团； X为-CH2-、-O-或-NH-，Y为-O-或-NH-；其中 （其中Z为-0-、-S-、-S(O)-、-S(O)2-、-CH2-、-CH(OH)-， 或 a和b分别独立为1至4的整数，且a和b的总和不超过5）； R2为可以被较低烷基基团取代的芳基烷基基团； R3为氢原子或较低烷基基团； R4为较低烷基基团； A为羟基，B为氢原子，或者A和B与相邻的碳原子结合在一起，描述了一种药学上可接受的酸盐或其酯。本发明的化合物具有对肾素的抑制活性，并可用作降压药。
• CATIONIC LIPIDS, METHODS FOR PREPARING THE SAME, AND DELIVERY SYSTEMS HAVING ABILITY TO TRANSITION INTO CELLS COMPRISING THE SAME
  申请人：Park Myung-Ok

  公开号：US20130123485A1

  公开（公告）日：2013-05-16

  The present invention provides cationic lipids, methods for preparing the same, and delivery systems comprising the same. The present invention can provide cationic lipids which enhance the efficiency of intracellular or in vivo delivery of multiple-anionic target compounds such as drugs, anticancer agents, nucleic acids, etc., have no intracellular toxicity, but show increased stability, methods for preparing the same, and delivery systems comprising the same.

  本发明提供了阳离子脂质、其制备方法以及包含该脂质的传递系统。本发明可以提供增强多阴离子靶向化合物（如药物、抗癌剂、核酸等）在细胞内或体内传递效率的阳离子脂质，不具有细胞内毒性，但表现出增加的稳定性，以及其制备方法和包含该脂质的传递系统。
• [EN] NOVEL ANTI-INFECTIVES<br/>[FR] NOUVEAUX ANTI-INFECTIEUX
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003099801A1

  公开（公告）日：2003-12-04

  Compounds useful as HCV anti-infectives are disclosed. Also disclosed are methods of making and using the same.

  抗丙型肝炎病毒感染的有用化合物已被披露。同时还披露了制备和使用这些化合物的方法。
• Pharmaceuticals
  申请人：——

  公开号：US20020147229A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula (I) 1 as well as the use of such compounds in pharmaceutical compositions and methods of treatment. The compounds described herein represent a class of TAFIla inhibitors suitable for use in treating conditions such as thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

  本发明提供了式(I)1的化合物，以及这些化合物在制药组合物和治疗方法中的应用。本文描述的化合物代表了一类适用于治疗血栓形成、动脉粥样硬化、粘连、皮肤瘢痕、癌症、纤维化疾病、炎症性疾病以及那些受益于维持或增强体内激肽酶激活因子Ⅰ（TAFIla）抑制剂的疾病的化合物。